Abstract:Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide; 82% of the cases occur in developing countries, with 55% occurring in China [1]. Liver transplantation (LT), a potentially curative thera peutic modality of HCC, allows radical extirpation of the cancer and restores normal liver function. There is increasing evidence that, in the long term, LT will be the best therapeutic option for cirrhosis-associated HCC [2]. Unfortunately, the recurrence rate is high in HCC patients who undergo LT, which markedly reduces the longterm and medium-term survival of HCC patients [3]. Therefore, risk estimation of post-transplant tumor recurrence is an essential element in selecting a subset of HCC patients for LT. In clinical practice, this risk estimation is based on the number and size of the nodules, and microscopic/macroscopic vascular invasion; and selection criteria for LT have been established to select HCC patients according to these clinical features. The Milan criteria proposed by Mazzaferro and his colleagues – a single lesion of 5 cm or smaller in diameter, or three lesions each smaller than 3 cm in diameter, and without macroscopic vascular invasion – have been accepted worldwide for identifying candidates with good prognosis and low recurrence rates [4]. The Milan criteria were chosen in an attempt to minimize the difference in outcomes between transplanted HCC patients and those who did not have HCC, and these criteria have been adopted for organ allocation in the USA and in Europe [5,6]. Despite their proven utility, many recent data have suggested that these criteria are too restrictive, and many patients with tumor burdens outside the Milan criteria may potentially benefit from LT. Moreover, limiting LT to HCC patients within the Milan criteria may be unjust for those outside of the criteria who could have a favorable outcome with LT. Several expansions of the Milan criteria have been proposed. Yao and coworkers at the University of California, San Francisco (UCSF; CA, USA) reported that LT candidates with a solitary tumor of 6.5 cm in diameter or smaller, or three or fewer nodules with the largest lesion no larger than 4.5 cm in diameter, and a total tumor diameter no larger than 8 cm (the so-called UCSF criteria) achieved excellent results following LT that were not different from those for HCC patients within the Milan criteria [7]. Although the UCSF criteria have been validated by several groups [8], these criteria have not been accepted unanimously, which may be related to the results of a large multi center study that suggested the UCSF criteria to be associated with a 5-year survival rate of less than 50% when applied to preoperative evaluation [9]. In addition, the UCSF criteria allow LT for large tumors, which have been proven to be associated with post-transplant metastatic recurrence [10]. Lastly, both the Milan and the UCSF criteria exclude those patients with more than three nodules, who may obtain good outcomes if the tumors are of a reasonable size. Toso and his colleagues proposed an expansion of the current allocation criteria Zhi Dai, PhD Liver Cancer Institute, Shanghai 200032, PR China dai.zhi@zs-hospital.sh.cn

Smaller Grafts Do Not Imply Early Recurrence in Recipients Transplanted for Hepatocellular Carcinoma: A Chinese Experience

Influence of graft size matching on outcomes of infantile living donor liver transplantation

Small graft size and hepatocellular carcinoma outcomes in living donor liver transplantation: a retrospective multicentric cohort study

No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Living Donor Liver Transplantation

Graft Size Alone Should Not Affect Donors Selection and Be Used to Predict the Prognosis of Recipients after Living Donor Liver Transplantation

Survival In Liver Transplant Recipients With Hepatitis B- Or Hepatitis C-Associated Hepatocellular Carcinoma: The Chinese Experience From 1999 To 2010

Effect of Graft Size Matching on Pediatric Living-Donor Liver Transplantation at a Single Center

Outcome of Hepatocellular Carcinoma Treated by Liver Transplantation: Comparison of Living Donor and Deceased Donor Transplantation.

Development of Models to Predict Early Post-Transplant Recurrence of Hepatocellular Carcinoma That Also Integrate the Quality and Characteristics of the Liver Graft: A National Registry Study in China.

Early Outcomes of Implanting Larger-Sized Grafts in Deceased Donor Liver Transplantation.

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Outcome of Patients Undergoing Right Lobe Living Donor Liver Transplantation with Small-for-size Grafts

Clinical Outcomes and Risk Factors of Hepatocellular Carcinoma Treated by Liver Transplantation: A Multi-Centre Comparison of Living Donor and Deceased Donor Transplantation

Utilization of Elderly Donors in Liver Transplantation for Patients with Hepatocellular Carcinoma: A National Retrospective Cohort Study of China

553 LIVER TRANSPLANTATION FOR HEPATITIS B VIRUS BACKGROUND HEPATOCELLULAR CARCINOMA: A PROSPECTIVE STUDY COMPARING MILAN AND HANGZHOU CRITERIA AT A SINGLE TRANSPLANTATION CENTER IN CHINA

Using a Small-for-size Graft Might Attribute to the Future Use of Left-Lobe Living Graft in Adult to Adult Living Donor Liver Transplantation.

A Single‐center Retrospective Analysis of Liver Transplantation on 255 Patients with Hepatocellular Carcinoma

Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma?

Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study.

The Stratifying Value of Hangzhou Criteria in Liver Transplantation for Hepatocellular Carcinoma.

Outcome of using small-for-size grafts in living donor liver transplantation recipients with high model for end-stage liver disease scores: a single center experience.